LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Ramírez-Rangel, Pamela"
  2. AU="Omar, Michael"
  3. AU="Flores-Campos, Rocío"
  4. AU="Pandit, Jayvardhan"
  5. AU="Peter M. Visscher"
  6. AU=Martn-Begu Nieves
  7. AU="Kiang, David"
  8. AU="Helal, Shaaban R"
  9. AU=Meltzer H Y
  10. AU="Gambhir, Prakash S"
  11. AU="El-Sayed, Saad A."
  12. AU="Hena Das"

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Large, Negative T Waves, Beyond Ischemia and Beyond Arrhythmias.

    Aceituno-Melgar, Jorge E / Sánchez-Contreras, C Alicia / Ramírez-Rangel, Pamela

    Annals of emergency medicine

    2023  Volume 82, Issue 2, Page(s) 222–225

    MeSH term(s) Humans ; Arrhythmias, Cardiac ; Ischemia
    Language English
    Publishing date 2023-07-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603080-4
    ISSN 1097-6760 ; 0196-0644
    ISSN (online) 1097-6760
    ISSN 0196-0644
    DOI 10.1016/j.annemergmed.2022.12.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Women with Acute Myocardial Infarction: Clinical Characteristics, Treatment, and In-Hospital Outcomes from a Latin American Country.

    Arias-Mendoza, Alexandra / González-Pacheco, Héctor / Álvarez-Sangabriel, Amada / Gopar-Nieto, Rodrigo / Rodríguez-Chávez, Laura Leticia / Araiza-Garaygordobil, Diego / Ramírez-Rangel, Pamela / Martínez, Daniel Sierra-Lara / Del Carmen Lacy-Niebla, María / Briseño-De la Cruz, José Luis / Juárez-Tolen, Jessica / Mendoza-García, Salvador / Altamirano-Castillo, Alfredo

    Global heart

    2023  Volume 18, Issue 1, Page(s) 19

    Abstract: Background: Women are underrepresented in acute myocardial infarction (AMI) studies. Furthermore, there is scarce information regarding women with AMI in Latin America.: Aims: To describe the presentation, clinical characteristics, risk factor burden, ...

    Abstract Background: Women are underrepresented in acute myocardial infarction (AMI) studies. Furthermore, there is scarce information regarding women with AMI in Latin America.
    Aims: To describe the presentation, clinical characteristics, risk factor burden, evidence-based care, and in-hospital outcome in a population of women with AMI admitted to a coronary care unit (CCU) in Mexico.
    Methods: Retrospective cohort study including patients with AMI admitted from January 2006 to December 2021 in a CCU. We identified patients with ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). We described demographic characteristics, clinical variables, treatment, and in-hospital outcomes according to gender. Cox regression analysis was used to identify predictors of mortality.
    Results: Our study included 12,069 patients with AMI, of whom 7,599 had STEMI and 4,470 had NSTEMI. Women represented 19.6% of the population. Women had higher rates of hypertension, diabetes, stroke, and atrial fibrillation than men. For STEMI, women were less likely to receive reperfusion therapy (fibrinolysis; 23.7 vs. 28.5%, p < 0.001 and primary percutaneous coronary intervention (PCI); 31.2 vs. 35.1%, p = 0.001) and had more major adverse events than men: heart failure (4.2 vs. 2.5%, p = 0.002), pulmonary edema (3.4% vs. 1.7%, p < 0.001), major bleeding (2.1% vs. 1%, p = 0.002), stroke (1.3% vs. 0.6%, p = 0.008), and mortality (15.1% vs. 8.1%, p < 0.001). For NSTEMI, women were less likely to undergo coronary angiography or PCI and had more major bleeding and mortality. Multivariate Cox regression analysis revealed that females had an increase in mortality in STEMI and NSTEMI (HR 1.21, CI 1.01-1.47, p = 0.05 and HR 1.39, CI 1.06-1.81, p = 0.01).
    Conclusion: Real-world evidence from a hospital in a Latin American low- to middle-income country (LMIC) showed that women with AMI had more comorbidities, received less reperfusion treatment or invasive strategies, and had worse outcomes. In STEMI and NSTEMI, female gender represented an independent predictor of in-hospital mortality.
    MeSH term(s) Male ; Humans ; Female ; ST Elevation Myocardial Infarction/epidemiology ; ST Elevation Myocardial Infarction/therapy ; Non-ST Elevated Myocardial Infarction/diagnosis ; Non-ST Elevated Myocardial Infarction/epidemiology ; Non-ST Elevated Myocardial Infarction/therapy ; Latin America/epidemiology ; Percutaneous Coronary Intervention ; Retrospective Studies ; Myocardial Infarction/epidemiology ; Myocardial Infarction/therapy ; Risk Factors ; Hemorrhage ; Hospitals ; Stroke ; Treatment Outcome ; Registries
    Language English
    Publishing date 2023-04-20
    Publishing country England
    Document type Editorial
    ZDB-ID 2629633-0
    ISSN 2211-8179 ; 2211-8160
    ISSN (online) 2211-8179
    ISSN 2211-8160
    DOI 10.5334/gh.1196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID).

    Absalón-Aguilar, Abdiel / Rull-Gabayet, Marina / Pérez-Fragoso, Alfredo / Mejía-Domínguez, Nancy R / Núñez-Álvarez, Carlos / Kershenobich-Stalnikowitz, David / Sifuentes-Osornio, José / Ponce-de-León, Alfredo / González-Lara, Fernanda / Martín-Nares, Eduardo / Montesinos-Ramírez, Sharon / Ramírez-Alemón, Martha / Ramírez-Rangel, Pamela / Márquez, Manlio F / Plata-Corona, Juan Carlos / Juárez-Vega, Guillermo / Gómez-Martín, Diana / Torres-Ruiz, Jiram

    Journal of general internal medicine

    2021  Volume 37, Issue 1, Page(s) 4–14

    Abstract: Background: Colchicine is an available, safe, and effective anti-inflammatory drug and has been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID-19 patients has not been thoroughly demonstrated.: Objective: To ... ...

    Abstract Background: Colchicine is an available, safe, and effective anti-inflammatory drug and has been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID-19 patients has not been thoroughly demonstrated.
    Objective: To address the safety and efficacy of colchicine in hospitalized patients with severe COVID-19.
    Design: We conducted a triple-blind parallel non-stratified placebo-controlled clinical trial.
    Participants: We recruited 116 hospitalized patients with severe COVID-19 in Mexico.
    Interventions: Patients were randomized to receive 1.5 mg of colchicine or placebo at the time of the recruitment in the study (baseline) and 0.5 mg BID PO to complete 10 days of treatment.
    Main measures: The primary composite outcome was the progression to critical disease or death. Besides, we evaluated immunological features at baseline and after recovery or disease progression in 20 patients.
    Key results: Fifty-six patients were allocated to colchicine and 60 patients received placebo. The study was suspended after the second interim analysis demonstrated colchicine had no effect on the primary outcome (OR 0.83, 95%CI 0.35-1.93, P = 0.67), nor in the days of ICU and hospital stays. Adverse events were similar between groups (OR 1.63, 95% CI 0.66-3.88, P = 0.37). After colchicine treatment, patients had higher BUN and lower serum levels of IL-8, IL-12p70, and IL-17A.
    Conclusions: Colchicine is safe but not effective in the treatment of severe COVID-19.
    Trial registration: ClinicalTrials.gov Identifier: NCT04367168.
    MeSH term(s) Colchicine/adverse effects ; Hospitalization ; Humans ; SARS-CoV-2 ; Treatment Outcome ; COVID-19 Drug Treatment
    Chemical Substances Colchicine (SML2Y3J35T)
    Language English
    Publishing date 2021-11-09
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 639008-0
    ISSN 1525-1497 ; 0884-8734
    ISSN (online) 1525-1497
    ISSN 0884-8734
    DOI 10.1007/s11606-021-07203-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top